<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Endocrinol (Lausanne)</journal-id><journal-id journal-id-type="iso-abbrev">Front Endocrinol (Lausanne)</journal-id><journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id><journal-title-group><journal-title>Frontiers in Endocrinology</journal-title></journal-title-group><issn pub-type="epub">1664-2392</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40013314</article-id><article-id pub-id-type="pmc">PMC11860089</article-id><article-id pub-id-type="doi">10.3389/fendo.2025.1502545</article-id><article-categories><subj-group subj-group-type="heading"><subject>Endocrinology</subject><subj-group><subject>Case Report</subject></subj-group></subj-group></article-categories><title-group><article-title>Case report: Hypoparathyroidism-sensorineural hearing loss-renal dysplasia without febrile seizures: a novel mutation in the GATA3 gene</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Haibin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yudi</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1801567"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Xueyao</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Yongzhen</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1786233"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Endocrinology, Changsha Hospital of Hunan Normal University</institution>, <addr-line>Changsha, Hunan</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Department of Endocrinology, The Fourth Hospital of Changsha</institution>, <addr-line>Changsha, Hunan</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Department of Pediatrics, The Second Xiangya Hospital, Central South University</institution>, <addr-line>Changsha, Hunan</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Ammar Husami, Cincinnati Children&#x02019;s Hospital Medical Center, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Hao Zhang, Shanghai Jiao Tong University, China</p><p>Yilun Tao, Changzhi Maternal and Child Care Hospital, China</p></fn><corresp id="fn001">*Correspondence: Yongzhen Li, <email xlink:href="mailto:507271@csu.edu.cn">507271@csu.edu.cn</email>
</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1502545</elocation-id><history><date date-type="received"><day>27</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>21</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Chen, Zhang, Yang and Li</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Chen, Zhang, Yang and Li</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Objective</title><p>This study aims to summarize the diagnostic and treatment experience of a case of Hypoparathyroidism-Sensorineural Hearing Loss-Renal Dysplasia (HDR) syndrome caused by a heterozygous mutation in the GATA3 gene.</p></sec><sec><title>Methods</title><p>The diagnostic and treatment process of the patient with HDR syndrome in our hospital was compared and analyzed.</p></sec><sec><title>Results</title><p>A 9-month-old male infant with a history of poor physical condition and increased susceptibility to infections. At the age of 2 months, ptosis was observed in the left eye. Laboratory tests revealed decreased serum calcium, elevated blood phosphorus levels, and reduced parathyroid hormone (PTH) levels, indicating the presence of &#x0201c;Hypoparathyroidism&#x0201d;. Genetic testing identified a heterozygous mutation in the GATA3 gene in the patient, specifically a nucleotide change from G to T at position 800 (c.800G&#x0003e;T). This mutation resulted in the substitution of cysteine with phenylalanine at amino acid position 267 (p.C267F). The missense mutation was determined to be both pathogenic and novel.</p></sec><sec><title>Conclusion</title><p>Early genetic testing should be prioritized, and regular monitoring of kidney development and hearing status is essential. The reported case, featuring the novel GATA3 gene mutation c.800G&#x0003e;T (p.C267F), contributes to the enrichment of the genetic database.</p></sec></abstract><kwd-group><kwd>HDR syndrome</kwd><kwd>GATA3 gene</kwd><kwd>GATA3 mutation</kwd><kwd>novel mutation</kwd><kwd>pediatric</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Hunan Provincial Health Committee Foundation of China (no. B202306017169), Changsha Natural Science Foundation(no. kq2208314), Guidance Science and Technology Program Project for the Year 2021 in Changsha City (no. kzd21106) and National Natural Science Foundation (no. 82402169).</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="1"/><equation-count count="0"/><ref-count count="27"/><page-count count="7"/><word-count count="2451"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Pediatric Endocrinology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Hypoparathyroidism-Sensorineural Hearing Loss-Renal Dysplasia syndrome (HDR syndrome), also known as Barakat syndrome, is a rare autosomal dominant genetic disorder (<xref rid="B1" ref-type="bibr">1</xref>). HDR syndrome is primarily characterized by hypocalcemia-induced increased neuromuscular excitability, such as non-febrile seizures, muscle spasms, and myalgia (<xref rid="B2" ref-type="bibr">2</xref>). It is associated with hearing loss and abnormal kidney structure or function, caused by mutations in the GATA3 gene located on chromosome 10p14 (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). The GATA3 gene belongs to the dual zinc finger transcription factor family and consists of 6 exons that encode 444 amino acids, including 2 transactivation domains and 2 zinc finger domains (<xref rid="B5" ref-type="bibr">5</xref>). This gene plays a crucial role in embryonic development in vertebrates and is expressed in the developing parathyroid gland, inner ear, and kidneys (<xref rid="B6" ref-type="bibr">6</xref>). The incidence of HDR syndrome is still clear, with limited reports on the clinical phenotype and genotype of HDR syndrome patients in China. In this case, the patient had a novel heterozygous mutation in the GATA3 gene, C.800G&#x0003e;T (p.C267F), which has not been reported before. Pathogenic analysis suggests that this mutation can lead to amino acid changes and is considered pathogenic. Therefore, this study aims to investigate the clinical features and genotypes of HDR syndrome, providing a foundation for accurate diagnosis and improving our understanding of the syndrome. This research will contribute to early screening and diagnosis, reducing misdiagnosis and missed diagnoses.</p></sec><sec id="s2"><label>2</label><title>Case report</title><sec id="s2_1"><label>2.1</label><title>General information</title><p>A 9-month-old male infant, with a height of 72cm and a weight of 10Kg, was admitted to our hospital for the second time due to &#x0201c;recurrent fever for 3 days&#x0201d;. He exhibited a history of a weakened constitution. At 2 months of age, the patient presented with ptosis in the left eye (excluding myasthenia gravis). At 4 months of age, the patient was diagnosed with &#x0201c;viral encephalitis&#x0201d; and had a history of febrile seizures. An examination revealed the presence of a patent foramen ovale. At 7 months of age, the patient was admitted to our hospital due to recurrent symptoms of fever, cough, and wheezing. There is no history of hepatitis, known exposure, surgery, trauma, or blood transfusion. The patient has allergies to amoxicillin, cefadroxil, or cefuroxime. Vaccinations are up to date. There is no significant personal or family medical history.</p><p>In the ten days preceding this hospitalization, the patient experienced four episodes of breath-holding spells characterized by sudden breath-holding and cyanosis while crying. These episodes did not coincide with fever. During a prior hospitalization at another institution, the patient also exhibited bilateral thumb adduction and stiffness in the right lower limb, without tremors. However, the patient remained conscious and responsive to the mother&#x02019;s call, and the symptoms improved with calcium supplementation.</p></sec><sec id="s2_2"><label>2.2</label><title>Diagnosis and treatment process</title><p>During the patient&#x02019;s first hospitalization at 7 months old, the blood calcium level was normal, but during the current hospitalization, there was a decrease in serum calcium levels and an increase in blood phosphorus levels. Low levels of parathyroid hormone (PTH) were observed, indicating &#x0201c;hypoparathyroidism.&#x0201d; All other hormone levels were within the normal range. Transient proteinuria was observed (+). <xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref> presents the results of the biochemical examination during this hospitalization, while <xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref> illustrates the trends in blood calcium and PTH levels over the patient&#x02019;s age. Cardiac ultrasound revealed no abnormalities in cardiac structure or blood flow. Abdominal ultrasound, which examined the liver, gallbladder, pancreas, spleen, kidneys, and retroperitoneum, showed no significant abnormalities. Ultrasound of the parathyroid, thyroid, and cervical lymph nodes revealed multiple lymph nodes in both sides of the neck, with enlarged lymph nodes in the right II region. However, no apparent abnormalities were found in the thyroid or parathyroid. Head magnetic resonance imaging (MRI) with contrast showed no abnormalities. Regarding the patient&#x02019;s hearing examination, the infant passed the hearing screening (Otoacoustic Emissions test and Automated Auditory Brainstem Response test) at birth. During the hospitalization, the bilateral Auditory Brainstem Response (ABR) test was conducted and no abnormal electrophysiological changes were observed. Further genetic testing identified a heterozygous mutation in the GATA3 gene. The mutation occurred at nucleotide 800, where G was replaced by T (c.800G&#x0003e;T), resulting in the substitution of cysteine with phenylalanine at amino acid position 267 (p.C267F), indicating a missense mutation. No variations were detected in the same position in either the father or mother.</p><table-wrap position="float" id="T1"><label>Table&#x000a0;1</label><caption><p>The results of the biochemical examination of the patient during this hospitalization.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1">Index</th><th valign="top" align="center" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">Result</th><th valign="top" align="center" rowspan="1" colspan="1">Normal range</th></tr></thead><tbody><tr><td valign="top" align="center" rowspan="3" colspan="1">Immunoglobulin</td><td valign="top" align="center" rowspan="1" colspan="1">IgG</td><td valign="top" align="center" rowspan="1" colspan="1">8.32</td><td valign="top" align="center" rowspan="1" colspan="1">7.00~16.00(g/l)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">IgA</td><td valign="top" align="center" rowspan="1" colspan="1">0.70</td><td valign="top" align="center" rowspan="1" colspan="1">0.70~4.00(g/l)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">IgM</td><td valign="top" align="center" rowspan="1" colspan="1">1.10</td><td valign="top" align="center" rowspan="1" colspan="1">0.40~2.30(g/l)</td></tr><tr><td valign="top" align="center" rowspan="5" colspan="1">Blood routine</td><td valign="top" align="center" rowspan="1" colspan="1">WBC</td><td valign="top" align="center" rowspan="1" colspan="1">13.39</td><td valign="top" align="center" rowspan="1" colspan="1">5.00~12.00(10^9/L)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">HB</td><td valign="top" align="center" rowspan="1" colspan="1">113</td><td valign="top" align="center" rowspan="1" colspan="1">110~160(g/L)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">RBC</td><td valign="top" align="center" rowspan="1" colspan="1">0.18</td><td valign="top" align="center" rowspan="1" colspan="1">0.10~0.40(10^12/L)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">PLT</td><td valign="top" align="center" rowspan="1" colspan="1">432</td><td valign="top" align="center" rowspan="1" colspan="1">100~400 (10^9/L)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">LYM</td><td valign="top" align="center" rowspan="1" colspan="1">5.10</td><td valign="top" align="center" rowspan="1" colspan="1">1.10~3.20(10^9/L)</td></tr><tr><td valign="top" align="center" rowspan="4" colspan="1">Biochemistry</td><td valign="top" align="center" rowspan="1" colspan="1">AST</td><td valign="top" align="center" rowspan="1" colspan="1">41.5</td><td valign="top" align="center" rowspan="1" colspan="1">15.0~40.0(U/L)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">ALT</td><td valign="top" align="center" rowspan="1" colspan="1">18.6</td><td valign="top" align="center" rowspan="1" colspan="1">9.0~50.0(U/L)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">Cr</td><td valign="top" align="center" rowspan="1" colspan="1">30.0</td><td valign="top" align="center" rowspan="1" colspan="1">44.0~133.0(&#x003bc;mol/L)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">BUN</td><td valign="top" align="center" rowspan="1" colspan="1">2.80</td><td valign="top" align="center" rowspan="1" colspan="1">2.90~7.14(mmol/L)</td></tr><tr><td valign="top" align="center" rowspan="5" colspan="1">Thyroid function&#x000a0;</td><td valign="top" align="center" rowspan="1" colspan="1">FT3</td><td valign="top" align="center" rowspan="1" colspan="1">2.72</td><td valign="top" align="center" rowspan="1" colspan="1">1.58~3.91(pg/ml)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">FT4</td><td valign="top" align="center" rowspan="1" colspan="1">1.12</td><td valign="top" align="center" rowspan="1" colspan="1">0.70~1.48(ng/dl)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">TSH</td><td valign="top" align="center" rowspan="1" colspan="1">3.28</td><td valign="top" align="center" rowspan="1" colspan="1">0.35~4.49(uIU/ml)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">A-TG</td><td valign="top" align="center" rowspan="1" colspan="1">0.426</td><td valign="top" align="left" rowspan="1" colspan="1">0.000~4.110(Iu/ml)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">A-TPO</td><td valign="top" align="center" rowspan="1" colspan="1">0.403</td><td valign="top" align="center" rowspan="1" colspan="1">0.000~5.610(Iu/ml)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">Urinalysis</td><td valign="top" align="center" rowspan="1" colspan="1">Urine protein</td><td valign="top" align="center" rowspan="1" colspan="1">negative</td><td valign="top" align="center" rowspan="1" colspan="1">negative</td></tr></tbody></table><table-wrap-foot><fn><p>WBC, White blood cell; HB, Hemoglobin; RBC, Red blood cell; PLT, Platelet; LYM, Lymphocyte; AST, Aspertate Aminotransferase; ALT, Glutamic-pyruvic transaminase; CERA, Creatinine; BUN, Blood urea nitrogen; FT3, Free Triiodothyronine; FT4, Free thyroxine, TSH, Thyroid-stimulating hormone; A-TG, Anti-thyroglobulin antibodies, A-TPO, Anti-thyroid peroxidase.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="f1"><label>Figure&#x000a0;1</label><caption><p>The trend of blood calcium and PTH levels changes in the patient.</p></caption><graphic xlink:href="fendo-16-1502545-g001" position="float"/></fig><p>After admission, the patient was treated with anti-infective, antitussive, bronchodilator, intravenous calcium supplements, and oral calcitriol, and showed improvement upon discharge. Following discharge, the child was regularly monitored for blood calcium and parathyroid hormone (PTH) levels at the outpatient clinic, and the oral calcitriol dosage was dynamically adjusted based on the results. Currently, the blood calcium levels are maintained within the normal range, and the parathyroid hormone levels have improved compared to before. (see <xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref>).</p></sec><sec id="s2_3"><label>2.3</label><title>Genetic testing</title><p>In order to investigate the underlying cause of the patient&#x02019;s recurrent pneumonia, wheezing, episodes of breath-holding without fever, hypoparathyroidism, hypocalcemia, and isolated ptosis, whole-exome gene sequencing and copy number variation analysis were performed.</p><p>The genetic testing results (depicted in <xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2</bold>
</xref>) disclosed a heterozygous mutation within the GATA3 gene, specifically at nucleotide position 800 (located in exon 4; reference sequence: NM_001002295), where guanine (G) was substituted by thymine (T). This mutation results in an amino acid alteration from cysteine to phenylalanine at position 267 (designated as p.C267F).According to the latest ACMG guidelines, this variant is provisionally classified as a likely pathogenic variant based on the following criteria:PS2: The variant was confirmed to be <italic>de novo</italic> through family segregation analysis, as no variations were found in the same position in either the father or mother; PM2_Supporting: The variant is rare in the general population, as indicated by its frequency (-) in the normal population database.PP3: Bioinformatics protein function prediction software REVEL predicts the variant to be deleterious. Additionally, SIFT, PolyPhen_2, MutationTaster, and GERP+ also predict the variant to be deleterious. There are no relevant reports on this specific position in the literature database, and the ClinVar database does not provide any pathogenic analysis results for this variant.</p><fig position="float" id="f2"><label>Figure&#x000a0;2</label><caption><p>The results of peripheral blood whole-exome sequencing and CNV analysis, as well as Sanger validation, for the patient and their parents.</p></caption><graphic xlink:href="fendo-16-1502545-g002" position="float"/></fig><p>Functional prediction (see <xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3</bold>
</xref>): The GATA3 gene&#x02019;s wild-type three-dimensional model was obtained from the SWISS-MODEL database (<ext-link xlink:href="https://swissmodel.expasy.org/" ext-link-type="uri">https://swissmodel.expasy.org/</ext-link>) and visualized using PyMOL (<ext-link xlink:href="https://pymol.org/2/" ext-link-type="uri">https://pymol.org/2/</ext-link>). Structural analysis of the Mut-GATA3 protein showed that the p.C267F mutation led to the substitution of the polar neutral amino acid cysteine with the nonpolar hydrophobic amino acid phenylalanine, without affecting hydrogen bonding.</p><fig position="float" id="f3"><label>Figure&#x000a0;3</label><caption><p>Functional prediction. In the cartoon structure shown in the figure, blue represents &#x003b1;-helices, purple represents &#x003b2;-sheets, and pink loops represent loop structures. The observed hydrogen bonds are depicted as stick structures, with each color representing a different atom: yellow for carbon (C), gray for hydrogen (H), blue for nitrogen (N), red for oxygen (O), and orange for sulfur (S).</p></caption><graphic xlink:href="fendo-16-1502545-g003" position="float"/></fig></sec></sec><sec sec-type="discussion" id="s3"><label>3</label><title>Discussion</title><p>HDR syndrome is a rare autosomal dominant disorder, with GATA3 currently being the only known gene associated with HDR syndrome. Haploinsufficiency of GATA3 is considered a potential cause of HDR syndrome (<xref rid="B7" ref-type="bibr">7</xref>). The diagnosis of HDR syndrome is typically based on the identification of clinical symptoms, and the detection of haploinsufficiency or submicroscopic deletions on chromosome 10p14 through DNA analysis can help confirm the diagnosis (<xref rid="B8" ref-type="bibr">8</xref>).</p><p>The clinical manifestations of patients with HDR syndrome are heterogeneous, even among individuals with the same mutation (<xref rid="B9" ref-type="bibr">9</xref>). Studies have shown that only 53.7% of patients exhibit the full HDR triad, while the remaining patients display only two or one of the characteristics (<xref rid="B2" ref-type="bibr">2</xref>). Sensorineural hearing loss is often the initial manifestation of HDR syndrome and is typically present at birth. The severity of hearing impairment varies but tends to worsen with age (<xref rid="B10" ref-type="bibr">10</xref>). GATA3 plays a crucial role in the development of the cochlear anterior sensory domain and spiral ganglion neurons during embryogenesis, affecting all hair cells and supporting cells in the cochlea. This defect can persist from early infancy to adulthood (<xref rid="B11" ref-type="bibr">11</xref>). Despite the fact that this patient passed the hearing screening at birth and showed no abnormal electrophysiological changes in the bilateral ABR test, due to the infant&#x02019;s young age (9 months), a pure tone audiometry (PTA) test could not be fully conducted. Therefore, continuous follow-up and monitoring are still necessary. Hypoparathyroidism manifests as symptomatic or asymptomatic hypocalcemia, including sensory abnormalities, tetany of hands and feet, hand and foot convulsions, seizures, and other symptoms (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). In this case, the patient&#x02019;s initial diagnosis of hypoparathyroidism was based on the observation of bilateral thumb adduction and palm rigidity, accompanied by rigidity in the right lower limb. These symptoms were alleviated after calcium supplementation. Additionally, the child&#x02019;s PTH levels remained persistently below the normal range. Previous studies in heterozygous GATA3 gene knockout mice have shown smaller parathyroid glands. Additionally, low calcium-induced hypocalcemia with low vitamin D intake does not increase parathyroid proliferation or PTH secretion (<xref rid="B14" ref-type="bibr">14</xref>). These findings align with the observed hypocalcemia and low PTH levels in our clinical observations.</p><p>The severity of renal involvement in HDR syndrome can vary, ranging from no renal abnormalities to various conditions such as renal dysplasia, hypoplasia, cystic kidneys, and bladder-ureter reflux. In some cases, patients may progress to late-stage chronic kidney disease, necessitating renal replacement therapy (<xref rid="B15" ref-type="bibr">15</xref>). Studies have shown that the prognosis of HDR syndrome depends on the nature and severity of renal disease, with renal developmental abnormalities typically associated with a poorer prognosis (<xref rid="B16" ref-type="bibr">16</xref>).In this case, no renal abnormalities were detected in the patient, potentially due to their young age and the kidneys still being in the developmental process without exhibiting apparent abnormalities. However, it is crucial not to relax the monitoring of these clinical symptoms. Ikeuchi et&#x000a0;al. (<xref rid="B17" ref-type="bibr">17</xref>) reported a case of an HDR patient who initially presented with primary hypoparathyroidism and right sensorineural hearing loss in the neonatal period, but no renal abnormalities were observed at that time. It was not until the patient reached 11 years old that right renal hypoplasia was discovered, despite the absence of evident clinical symptoms. In addition to the typical triad, previous literature has also reported other symptoms, including congenital heart defects, biliary atresia, pituitary hypofunction, genital anomalies, and diabetes (<xref rid="B18" ref-type="bibr">18</xref>&#x02013;<xref rid="B22" ref-type="bibr">22</xref>).Therefore, comprehensive evaluation and regular follow-up are essential for managing patients with HDR syndrome to detect and address any potential complications.</p><p>The GATA3 protein comprises two N-terminal transactivation domains (TA1, TA2) and two C-terminal zinc finger domains (ZnF1, ZnF2). ZnF2 specifically recognizes and binds to the N-(A/T)GATA(T/G)-C sequence in DNA. ZnF1 stabilizes the binding of ZnF2 to DNA and interacts with various zinc finger proteins (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>). Lemos et&#x000a0;al. compiled and analyzed data from 124 reported HDR syndrome families (including 177 patients), summarizing the GATA3 gene mutations found within these families. These mutations included 40% frameshift mutations, 23% missense mutations, 14% nonsense mutations, 6% splice site mutations, 1% in-frame deletions or insertions, 15% whole-gene deletions, and 1% gene duplications. There were no apparent mutation hotspots across the entire GATA3 gene, but missense mutations clustered within or near the ZnF1 or ZnF2 domains of the GATA3 gene (<xref rid="B2" ref-type="bibr">2</xref>). In this study, p.C267F is a missense mutation where the polar neutral amino acid cysteine is changed to the non-polar hydrophobic amino acid phenylalanine, located within ZnF1, resulting in a decrease in the affinity of the DNA binding site. This site has not been reported before and has important clinical significance for enriching the mutation spectrum of HDR genes.</p><p>Symptomatic management is typically the main approach for treating HDR syndrome. The treatment goal for patients with hypoparathyroidism is to alleviate symptoms and maintain serum calcium levels within the normal low range. However, it is important to note that patients with hypoparathyroidism have reduced renal reabsorption of calcium due to low levels of PTH, which makes them more susceptible to hypercalciuria compared to individuals without the condition. Furthermore, HDR syndrome patients have an inherent risk of kidney disease. Therefore, close monitoring and follow-up are necessary, and measures should be taken to prevent iatrogenic kidney stone formation (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). For hearing impairment, the use of conventional hearing aids or cochlear implants can help restore hearing. Early diagnosis and intervention for hearing impairment are crucial (<xref rid="B27" ref-type="bibr">27</xref>). Genetic counseling is particularly important for autosomal dominant genetic disorders like HDR syndrome. It is recommended to seek early evaluation by clinical geneticists. Additionally, attention should be given to newborn hearing screening, prenatal ultrasound examinations, and early identification of hearing or renal defects to provide important opportunities for screening, diagnosis, guidance for reproductive choices, and early intervention.</p><p>The analysis of this case&#x02019;s diagnosis and treatment process offers valuable insights for the clinical management of HDR syndrome. Clinicians should exercise caution when diagnosing HDR syndrome in young patients presenting with hypoparathyroidism, but without evident kidney or hearing symptoms. Early evaluation by clinical geneticists is recommended for autosomal dominant genetic disorders, and emphasis should be placed on newborn hearing screening and continuous monitoring of kidney development. Furthermore, the identification of the novel GATA3 gene variant c.800G&#x0003e;T (p.C267F) in this case contributes to the enrichment of the genetic database.</p></sec></body><back><sec sec-type="data-availability" id="s4"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.</p></sec><sec sec-type="ethics-statement" id="s5"><title>Ethics statement</title><p>The studies involving humans were approved by Ethics Committee of Xiangya Second Hospital, Central South University. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants&#x02019; legal guardians/next of kin. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p></sec><sec sec-type="author-contributions" id="s6"><title>Author contributions</title><p>HC: Funding acquisition, Writing &#x02013; original draft, Data curation, Visualization. YZ: Data curation, Visualization, Writing &#x02013; original draft. XY: Data curation, Supervision, Writing &#x02013; original draft. YL: Writing &#x02013; review &#x00026; editing, Funding acquisition, Writing &#x02013; original draft.</p></sec><sec sec-type="COI-statement" id="s8"><title>Conflict of interest</title><p>The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s9"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s10"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barakat</surname><given-names>AY</given-names></name><name><surname>D&#x02019;Albora</surname><given-names>JB</given-names></name><name><surname>Martin</surname><given-names>MM</given-names></name><name><surname>Jose</surname><given-names>PA</given-names></name></person-group>. <article-title>Familial nephrosis, nerve deafness, and hypoparathyroidism</article-title>. <source>J Pediatr</source>. (<year>1977</year>) <volume>91</volume>:<page-range>61&#x02013;4</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S0022-3476(77)80445-9</pub-id>
</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lemos</surname><given-names>MC</given-names></name><name><surname>Thakker</surname><given-names>RV</given-names></name></person-group>. <article-title>Hypoparathyroidism, deafness, and renal dysplasia syndrome: 20 Years after the identification of the first GATA3 mutations</article-title>. <source>Hum Mutat</source>. (<year>2020</year>) <volume>41</volume>:<page-range>1341&#x02013;50</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/humu.24052</pub-id>
</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Joseph</surname><given-names>ADD</given-names></name><name><surname>Sirisena</surname><given-names>ND</given-names></name><name><surname>Kumanan</surname><given-names>T</given-names></name><name><surname>Sujanitha</surname><given-names>V</given-names></name><name><surname>Strelow</surname><given-names>V</given-names></name><name><surname>Yamamoto</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Hypoparathyroidism, Sensorineural deafness and renal disease (Barakat syndrome) caused by a reduced gene dosage in GATA3: a case report and review of literature</article-title>. <source>BMC Endocr Disord</source>. (<year>2019</year>) <volume>19</volume>:<fpage>111</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12902-019-0438-4</pub-id>
<pub-id pub-id-type="pmid">31660939</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoshino</surname><given-names>A</given-names></name><name><surname>Kawamoto</surname><given-names>S</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name><name><surname>Hidaka</surname><given-names>Y</given-names></name><name><surname>Muroya</surname><given-names>K</given-names></name><name><surname>Tokumoto</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>A case of hypoparathyroidism, sensorineural deafness, and renal dysplasia syndrome with kidney failure and recurrent pancreatitis: Answers</article-title>. <source>Pediatr Nephrol</source>. (<year>2021</year>) <volume>36</volume>:<page-range>4071&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00467-021-05190-w</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheon</surname><given-names>CK</given-names></name><name><surname>Kim</surname><given-names>GH</given-names></name><name><surname>Yoo</surname><given-names>HW</given-names></name></person-group>. <article-title>The first Korean case of HDR syndrome confirmed by clinical and molecular investigation</article-title>. <source>Yonsei Med J</source>. (<year>2015</year>) <volume>56</volume>:<page-range>300&#x02013;3</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3349/ymj.2015.56.1.300</pub-id>
</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Ki</surname><given-names>CS</given-names></name><name><surname>Hong</surname><given-names>SH</given-names></name><name><surname>Cho</surname><given-names>SY</given-names></name><name><surname>Jin</surname><given-names>DK</given-names></name></person-group>. <article-title>HDR syndrome with a novel mutation in GATA3 mimicking a congenital X-linked stapes gusher: a case report</article-title>. <source>BMC Med Genet</source>. (<year>2017</year>) <volume>18</volume>:<fpage>121</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12881-017-0484-6</pub-id>
<pub-id pub-id-type="pmid">29073906</pub-id>
</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van Esch</surname><given-names>H</given-names></name><name><surname>Groenen</surname><given-names>P</given-names></name><name><surname>Nesbit</surname><given-names>MA</given-names></name><name><surname>Schuffenhauer</surname><given-names>S</given-names></name><name><surname>Lichtner</surname><given-names>P</given-names></name><name><surname>Vanderlinden</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>GATA3 haplo-insufficiency causes human HDR syndrome</article-title>. <source>Nature</source>. (<year>2000</year>) <volume>406</volume>:<page-range>419&#x02013;22</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/35019088</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>YB</given-names></name><name><surname>Nie</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Xia</surname><given-names>WB</given-names></name><etal/></person-group>. <article-title>Clinical characteristics and molecular mechanisms of hypoparathyroidism related to GATA3 gene mutation</article-title>. <source>Zhonghua Nei Ke Za Zhi</source>. (<year>2022</year>) <volume>61</volume>:<page-range>,66&#x02013;71</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3760/cma.j.cn112138-20210519-00356</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Belge</surname><given-names>H</given-names></name><name><surname>Dahan</surname><given-names>K</given-names></name><name><surname>Cambier</surname><given-names>JF</given-names></name><name><surname>Benoit</surname><given-names>V</given-names></name><name><surname>Morelle</surname><given-names>J</given-names></name><name><surname>Bloch</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Clinical and mutational spectrum of hypoparathyroidism, deafness and renal dysplasia syndrome</article-title>. <source>Nephrol Dial Transplant</source>. (<year>2017</year>) <volume>32</volume>:<page-range>830&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/ndt/gfw271</pub-id>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>WX</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Ni</surname><given-names>Y</given-names></name><name><surname>Duan</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Novel heterozygous GATA3 and SLC34A3 variants in a 6-year-old boy with Barakat syndrome and hypercalciuria</article-title>. <source>Mol Genet Genomic Med</source>. (<year>2020</year>) <volume>8</volume>:<fpage>e1222</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/mgg3.1222</pub-id>
<pub-id pub-id-type="pmid">32155322</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>GATA3 maintains the quiescent state of cochlear supporting cells by regulating p27kip1</article-title>. <source>Sci Rep</source>. (<year>2014</year>) <volume>11</volume>:<fpage>15779</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41598-021-95427-3</pub-id>
</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barakat</surname><given-names>AJ</given-names></name><name><surname>Raygada</surname><given-names>M</given-names></name><name><surname>Rennert</surname><given-names>OM</given-names></name></person-group>. <article-title>Barakat syndrome revisited</article-title>. <source>Am J Med Genet A</source>. (<year>2018</year>) <volume>176</volume>:<page-range>1341&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/ajmg.a.v176.6</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alkaissi</surname><given-names>HR</given-names></name><name><surname>Banerji</surname><given-names>MA</given-names></name></person-group>. <article-title>Primary hypoparathyroidism presenting as idiopathic intracranial hypertension in a patient with barakat syndrome</article-title>. <source>Cureus</source>. (<year>2022</year>) <volume>14</volume>:<fpage>e24521</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.7759/cureus.24521</pub-id>
<pub-id pub-id-type="pmid">35651450</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grigorieva</surname><given-names>IV</given-names></name><name><surname>Mirczuk</surname><given-names>S</given-names></name><name><surname>Gaynor</surname><given-names>KU</given-names></name><name><surname>Nesbit</surname><given-names>MA</given-names></name><name><surname>Grigorieva</surname><given-names>EF</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Gata3-deficient mice develop parathyroid abnormalities due to dysregulation of the parathyroid-specific transcription factor Gcm2</article-title>. <source>J Clin Invest</source>. (<year>2010</year>) <volume>120</volume>:<page-range>2144&#x02013;55</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1172/JCI42021</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grigorieva</surname><given-names>IV</given-names></name><name><surname>Oszwald</surname><given-names>A</given-names></name><name><surname>Grigorieva</surname><given-names>EF</given-names></name><name><surname>Schachner</surname><given-names>H</given-names></name><name><surname>Neudert</surname><given-names>B</given-names></name><name><surname>Ostendorf</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>A novel role for GATA3 in mesangial cells in glomerular development and injury</article-title>. <source>J Am Soc Nephrol</source>. (<year>2019</year>) <volume>30</volume>:<page-range>1641&#x02013;58</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1681/ASN.2018111143</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>N</given-names></name><name><surname>Hori</surname><given-names>S</given-names></name><name><surname>Omori</surname><given-names>C</given-names></name><name><surname>Miyake</surname><given-names>M</given-names></name><name><surname>Anai</surname><given-names>S</given-names></name><name><surname>Torimoto</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Living-donor kidney transplantation for a patient with hypoparathyroidism, deafness, and renal dysplasia syndrome</article-title>. <source>IJU Case Rep</source>. (<year>2020</year>) <volume>3</volume>:<page-range>244&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/iju5.12205</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ikeuchi</surname><given-names>M</given-names></name><name><surname>Kiyota</surname><given-names>K</given-names></name><name><surname>Itonaga</surname><given-names>T</given-names></name><name><surname>Kawano-Matsuda</surname><given-names>F</given-names></name><name><surname>Ohata</surname><given-names>Y</given-names></name><name><surname>Fujiwara</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>A case of HDR syndrome coexisting with tetralogy of Fallot, with a novel GATA3 mutation, which manifested as a renal abscess</article-title>. <source>CEN Case Rep</source>. (<year>2021</year>) <volume>10</volume>:<page-range>241&#x02013;3</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s13730-020-00551-0</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kusakawa</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Hosoda</surname><given-names>A</given-names></name><name><surname>Araki</surname><given-names>E</given-names></name><name><surname>Matsuzaki</surname><given-names>Y</given-names></name><name><surname>Yamashita</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>A neonatal case of HDR syndrome and a vascular ring with a novel GATA3 mutation</article-title>. <source>Hum Genome Var</source>. (<year>2019</year>) <volume>6</volume>:<fpage>55</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41439-019-0087-1</pub-id>
<pub-id pub-id-type="pmid">31885872</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Higuchi</surname><given-names>Y</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name><name><surname>Yamashita</surname><given-names>M</given-names></name><name><surname>Fujii</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Tsukahara</surname><given-names>H</given-names></name></person-group>. <article-title>HDR syndrome in a Japanese girl with biliary atresia: a case report</article-title>. <source>BMC Pediatr</source>. (<year>2016</year>) <volume>16</volume>:<fpage>14</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12887-016-0550-9</pub-id>
<pub-id pub-id-type="pmid">26800885</pub-id>
</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Can</surname><given-names>M</given-names></name><name><surname>Karakurt</surname><given-names>F</given-names></name><name><surname>Kocabas</surname><given-names>M</given-names></name><name><surname>Cordan</surname><given-names>I</given-names></name><name><surname>Karakose</surname><given-names>M</given-names></name><name><surname>Kulaksizoglu</surname><given-names>M</given-names></name></person-group>. <article-title>HDR syndrome accompanying type 1 diabetes mellitus and hypopituitarism</article-title>. <source>Case Rep Endocrinol</source>. (<year>2019</year>) <volume>2019</volume>:<fpage>7276947</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1155/2019/7276947</pub-id>
<pub-id pub-id-type="pmid">31223507</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vallejo-Urrego</surname><given-names>MA</given-names></name><name><surname>Parra-Morales</surname><given-names>AM</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>A</given-names></name></person-group>. <article-title>HDR syndrome in a Colombian woman with a genital tract malformation: First case report in Latin America</article-title>. <source>Rev Salud Publica (Bogota)</source>. (<year>2018</year>) <volume>20</volume>:<page-range>637&#x02013;40</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.15446/rsap.v20n5.71057</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muroya</surname><given-names>K</given-names></name><name><surname>Mochizuki</surname><given-names>T</given-names></name><name><surname>Fukami</surname><given-names>M</given-names></name><name><surname>Iso</surname><given-names>M</given-names></name><name><surname>Fujita</surname><given-names>K</given-names></name><name><surname>Itakura</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Diabetes mellitus in a Japanese girl with HDR syndrome and GATA3 mutation</article-title>. <source>Endocr J</source>. (<year>2010</year>) <volume>57</volume>:<page-range>171&#x02013;4</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1507/endocrj.K09E-313</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Orkin</surname><given-names>SH</given-names></name></person-group>. <article-title>GATA-binding transcription factors in hematopoietic cells</article-title>. <source>Blood</source>. (<year>1992</year>) <volume>80</volume>:<page-range>575&#x02013;81</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1182/blood.V80.3.575.575</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nesbit</surname><given-names>MA</given-names></name><name><surname>Bowl</surname><given-names>MR</given-names></name><name><surname>Harding</surname><given-names>B</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Ayala</surname><given-names>A</given-names></name><name><surname>Crowe</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Characterization of GATA3 mutations in the hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome</article-title>. <source>J Biol Chem</source>. (<year>2004</year>) <volume>279</volume>:<page-range>22624&#x02013;34</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1074/jbc.M401797200</pub-id>
</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kostoglou-Athanassiou</surname><given-names>I</given-names></name><name><surname>Stefanopoulos</surname><given-names>D</given-names></name><name><surname>Karfi</surname><given-names>A</given-names></name><name><surname>Athanassiou</surname><given-names>P</given-names></name></person-group>. <article-title>Vitamin D deficiency in a patient with HDR syndrome</article-title>. <source>BMJ Case Rep</source>. (<year>2015</year>), <fpage>bcr2014208290</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1136/bcr-2014-208290</pub-id>
</mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kamezaki</surname><given-names>M</given-names></name><name><surname>Kusaba</surname><given-names>T</given-names></name><name><surname>Adachi</surname><given-names>T</given-names></name><name><surname>Yamashita</surname><given-names>N</given-names></name><name><surname>Nakata</surname><given-names>M</given-names></name><name><surname>Ota</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Unusual proliferative glomerulonephritis in a patient diagnosed to have hypoparathyroidism, sensorineural deafness, and renal dysplasia (HDR) syndrome with a novel mutation in the GATA3 gene</article-title>. <source>Intern Med</source>. (<year>2017</year>) <volume>56</volume>:<page-range>1393&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2169/internalmedicine.56.7930</pub-id>
</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gogorza</surname><given-names>MS</given-names></name><name><surname>Mena</surname><given-names>E</given-names></name><name><surname>Serra</surname><given-names>G</given-names></name><name><surname>Jim&#x000e9;nez</surname><given-names>A</given-names></name><name><surname>Noval</surname><given-names>M</given-names></name><name><surname>Pereg</surname><given-names>V</given-names></name></person-group>. <article-title>The hypoparathyroidism-deafness-renal dysplasia syndrome: A case report</article-title>. <source>Endocrinol Diabetes Nutr (Engl Ed)</source>. (<year>2018</year>) <volume>65</volume>:<page-range>187&#x02013;8</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.endien.2017.12.001</pub-id>
</mixed-citation></ref></ref-list></back></article>